Esmolol: A pharmacokinetic profile of a new cardioselective β-blocking agent
✍ Scribed by Avraham Yacobi; Ronald Kartzinel; Chii-Ming Lai; Check Y. Sum
- Publisher
- John Wiley and Sons
- Year
- 1983
- Tongue
- English
- Weight
- 241 KB
- Volume
- 72
- Category
- Article
- ISSN
- 0022-3549
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
The challenge in developing hypnotic agents for the treatment of insomnia is to balance the sedative effect needed at bedtime with the residual sedation on awakening. Zaleplon is a novel pyrazolopyrimidine hypnotic agent that acts as a selective agonist to the brain omega(1) receptor situated on the
Sixteen healthy men received iohexol intravenously at a concentration of 346 mg of iodine/mL. Doses of 500, 750, 1000, and 1500 mg of iodine/kg of body weight were administered to four volunteers each. Neither clearance nor percent of dose excreted in the urine showed any significant correlation wit
The objective of this study was to evaluate the pharmacokinetics of midaglizole, a new orally effective hypoglycaemic agent, in healthy male subjects. In Study I, volunteers were given single oral doses of 150, 200, 300, and 500 mg of midaglizole 20 min before breakfast. In Study 11, 200 mg of midag